Table 4.
Summary of different economic parameters for HA production using wild and recombinant microbial strains
| Scenarios/economic parameters | A | B | S1 | S2 | S3 | S4 | SE1 | BS1 | BS2 |
|---|---|---|---|---|---|---|---|---|---|
| Reference | 34a | 34b | 17 | ||||||
| Technology | Streptococci fermentation | Streptococci fermentation | Streptococci fermentation | B. subtillis A164Δ5 | B. subtilis 3NA | ||||
| Total capital investment (million US$) | 41.8 | 86.844 | 53.5 | 44.3 | 107 | 89.6 | 106.5 | 82.7 | 223.3 |
| Unit production cost (US$/kg) | 931 | 1665 | 1115 | 946 | 1691 | 1449 | 113 | 67 | 43 |
| Return on investment (ROI in %) | 46.12 | 50.64 | 32.6 | 43.5 | 42.5 | 53.1 | 43.6 | 66.4 | 78.3 |
| Payback time (years) | 2.17 | 1.97 | 3.07 | 2.30 | 2.35 | 1.88 | - | - | - |
| Net present value (NPV) (million US$) | 118.0 | 281.6 | 92.4 | 115.3 | 276.5 | 308.7 | 244.5 | 124.6 | 285.3 |
| Product for topical use (kg/year) | 20,000 | 17,944 | 20,000 | 20,000 | 19,067 | 19,067 | 1,222,357 | 622,912 | 1,426,255 |
| Product for injectable use (kg/year) | 0 | 2,056 | 0 | 0 | 871 | 871 | |||
| Percentual of HA diverted to injectable use | 10.28% | 4.36% | |||||||